Literature DB >> 29275316

The Positive Relationship Between γH2AX and PD-L1 Expression in Lung Squamous Cell Carcinoma.

Atsushi Osoegawa1, Hitomi Hiraishi2, Takafumi Hashimoto2, Yohei Takumi2, Miyuki Abe2, Hideya Takeuchi2, Michiyo Miyawaki2, Tatsuro Okamoto2, Kenji Sugio2.   

Abstract

BACKGROUND/AIM: Lung squamous cell carcinoma often arises from precancerous lesions where alterations in tumor suppressor genes and subsequent chromosomal instability are often observed due to carcinogen exposure. These tumors are often immunogenic; as such, immune checkpoint inhibitors are a promising therapeutic option. We hypothesized that the DNA damage response in tumor cells induces an immune response, thereby up-regulating programmed death-ligand 1 (PD-L1) expression on tumor cells, which in turn sensitizes them to anti-PD-1 therapy. PATIENTS AND METHODS: An immunohistochemical analysis was performed in 41 consecutive lung squamous cell carcinoma patients who underwent surgery at our institution between April 2013 and March 2014.
RESULTS: The analysis revealed a high PD-L1 expression in 15 patients (37%) (p=0.028). The PD-L1 expression was positively associated with the nuclear γH2AX expression (p=0.02), that was confirmed by immunofluorescent staining.
CONCLUSION: Our findings demonstrate that nuclear γH2AX expression is positively associated with the PD-L1 expression in lung squamous cell carcinoma. Copyright
© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  DNA damage response; Immune checkpoint inhibitor; lung squamous cell carcinoma

Mesh:

Substances:

Year:  2018        PMID: 29275316      PMCID: PMC5892638          DOI: 10.21873/invivo.11221

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  40 in total

1.  Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer.

Authors:  Kristin J Lastwika; Willie Wilson; Qing Kay Li; Jeffrey Norris; Haiying Xu; Sharon R Ghazarian; Hiroshi Kitagawa; Shigeru Kawabata; Janis M Taube; Sheng Yao; Linda N Liu; Joell J Gills; Phillip A Dennis
Journal:  Cancer Res       Date:  2015-12-04       Impact factor: 12.701

Review 2.  Role of Local Radiation Therapy in Cancer Immunotherapy.

Authors:  Sandra Demaria; Encouse B Golden; Silvia C Formenti
Journal:  JAMA Oncol       Date:  2015-12       Impact factor: 31.777

Review 3.  The functions and regulation of the PTEN tumour suppressor.

Authors:  Min Sup Song; Leonardo Salmena; Pier Paolo Pandolfi
Journal:  Nat Rev Mol Cell Biol       Date:  2012-04-04       Impact factor: 94.444

4.  Development of a Companion Diagnostic for Pembrolizumab in Non-Small Cell Lung Cancer Using Immunohistochemistry for Programmed Death Ligand-1.

Authors:  Marisa Dolled-Filhart; Charlotte Roach; Grant Toland; Dave Stanforth; Malinka Jansson; Gregory M Lubiniecki; Gary Ponto; Kenneth Emancipator
Journal:  Arch Pathol Lab Med       Date:  2016-08-23       Impact factor: 5.534

5.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

6.  PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project.

Authors:  Fred R Hirsch; Abigail McElhinny; Dave Stanforth; James Ranger-Moore; Malinka Jansson; Karina Kulangara; William Richardson; Penny Towne; Debra Hanks; Bharathi Vennapusa; Amita Mistry; Rasika Kalamegham; Steve Averbuch; James Novotny; Eric Rubin; Kenneth Emancipator; Ian McCaffery; J Andrew Williams; Jill Walker; John Longshore; Ming Sound Tsao; Keith M Kerr
Journal:  J Thorac Oncol       Date:  2016-11-29       Impact factor: 15.609

7.  The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition.

Authors:  Xiaofeng Jiang; Jun Zhou; Anita Giobbie-Hurder; Jennifer Wargo; F Stephen Hodi
Journal:  Clin Cancer Res       Date:  2012-10-24       Impact factor: 12.531

8.  Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.

Authors:  Naiyer A Rizvi; Matthew D Hellmann; Alexandra Snyder; Pia Kvistborg; Vladimir Makarov; Jonathan J Havel; William Lee; Jianda Yuan; Phillip Wong; Teresa S Ho; Martin L Miller; Natasha Rekhtman; Andre L Moreira; Fawzia Ibrahim; Cameron Bruggeman; Billel Gasmi; Roberta Zappasodi; Yuka Maeda; Chris Sander; Edward B Garon; Taha Merghoub; Jedd D Wolchok; Ton N Schumacher; Timothy A Chan
Journal:  Science       Date:  2015-03-12       Impact factor: 47.728

9.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Authors:  Hossein Borghaei; Luis Paz-Ares; Leora Horn; David R Spigel; Martin Steins; Neal E Ready; Laura Q Chow; Everett E Vokes; Enriqueta Felip; Esther Holgado; Fabrice Barlesi; Martin Kohlhäufl; Oscar Arrieta; Marco Angelo Burgio; Jérôme Fayette; Hervé Lena; Elena Poddubskaya; David E Gerber; Scott N Gettinger; Charles M Rudin; Naiyer Rizvi; Lucio Crinò; George R Blumenschein; Scott J Antonia; Cécile Dorange; Christopher T Harbison; Friedrich Graf Finckenstein; Julie R Brahmer
Journal:  N Engl J Med       Date:  2015-09-27       Impact factor: 91.245

Review 10.  GammaH2AX and cancer.

Authors:  William M Bonner; Christophe E Redon; Jennifer S Dickey; Asako J Nakamura; Olga A Sedelnikova; Stéphanie Solier; Yves Pommier
Journal:  Nat Rev Cancer       Date:  2008-11-13       Impact factor: 60.716

View more
  7 in total

1.  Assessment of TILs, IDO-1, and PD-L1 in resected non-small cell lung cancer: an immunohistochemical study with clinicopathological and prognostic implications.

Authors:  Martina Mandarano; Guido Bellezza; Maria Laura Belladonna; Benoit J Van den Eynde; Rita Chiari; Jacopo Vannucci; Giada Mondanelli; Vienna Ludovini; Ivana Ferri; Fortunato Bianconi; Rachele Del Sordo; Lucio Cagini; Elisa Albini; Giulio Metro; Francesco Puma; Angelo Sidoni
Journal:  Virchows Arch       Date:  2018-11-17       Impact factor: 4.064

2.  γH2AX, a DNA Double-Strand Break Marker, Correlates with PD-L1 Expression in Smoking-Related Lung Adenocarcinoma.

Authors:  Eiko Sakurai; Hisato Ishizawa; Yuka Kiriyama; Ayano Michiba; Yasushi Hoshikawa; Tetsuya Tsukamoto
Journal:  Int J Mol Sci       Date:  2022-06-15       Impact factor: 6.208

Review 3.  An Emerging Regulatory Role for the Tumor Microenvironment in the DNA Damage Response to Double-Strand Breaks.

Authors:  Tshering D Lama-Sherpa; Lalita A Shevde
Journal:  Mol Cancer Res       Date:  2019-11-01       Impact factor: 5.852

4.  countfitteR: efficient selection of count distributions to assess DNA damage.

Authors:  Jarosław Chilimoniuk; Alicja Gosiewska; Jadwiga Słowik; Romano Weiss; P Markus Deckert; Stefan Rödiger; Michał Burdukiewicz
Journal:  Ann Transl Med       Date:  2021-04

5.  Kynurenine/Tryptophan Ratio as a Potential Blood-Based Biomarker in Non-Small Cell Lung Cancer.

Authors:  Martina Mandarano; Elena Orecchini; Guido Bellezza; Jacopo Vannucci; Vienna Ludovini; Sara Baglivo; Francesca Romana Tofanetti; Rita Chiari; Elisabetta Loreti; Francesco Puma; Angelo Sidoni; Maria Laura Belladonna
Journal:  Int J Mol Sci       Date:  2021-04-22       Impact factor: 5.923

Review 6.  Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors.

Authors:  Sanjeevani Arora; Rodion Velichinskii; Randy W Lesh; Usman Ali; Michal Kubiak; Pranshu Bansal; Hossein Borghaei; Martin J Edelman; Yanis Boumber
Journal:  Adv Ther       Date:  2019-08-13       Impact factor: 3.845

Review 7.  The role of DNA damage repair (DDR) system in response to immune checkpoint inhibitor (ICI) therapy.

Authors:  Congqi Shi; Kaiyu Qin; Anqi Lin; Aimin Jiang; Quan Cheng; Zaoqu Liu; Jian Zhang; Peng Luo
Journal:  J Exp Clin Cancer Res       Date:  2022-09-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.